Summit Therapeutics Inc
SMMT
Company Profile
Business description
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Contact
601 Brickell Key Drive
Suite 1000
MiamiFL33131
USAT: +1 650 460-8308
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
159
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.80 | 45.70 | -0.50% |
| CAC 40 | 8,311.74 | 28.82 | -0.35% |
| DAX 40 | 24,914.88 | 62.19 | 0.25% |
| Dow JONES (US) | 49,500.93 | 48.95 | 0.10% |
| FTSE 100 | 10,446.35 | 43.91 | 0.42% |
| HKSE | 26,567.12 | 616.03 | -2.27% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,941.97 | 708.57 | -1.23% |
| NZX 50 Index | 13,198.18 | 248.19 | -1.85% |
| S&P 500 | 6,836.17 | 3.41 | 0.05% |
| S&P/ASX 200 | 8,917.60 | 1.60 | 0.02% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |